EUVIMEDEUVIMED entdecken
Crossref

Optimal Timing for Oral Anticoagulant Discontinuation and Prognosis After Successful Catheter Ablation for Atrial Fibrillation

Tomoya Iwawaki, Satoshi Yanagisawa, Yasuya Inden, Kiichi Miyamae, Hiroyuki Miyazawa, Takayuki Goto, Shun Kondo, Masaya Tachi, Taishi Fukushima, Takehiro Hiramatsu, Kentaro Adachi, Tsubasa Teraoka und 5 weitere

JACC: Clinical Electrophysiology · 2026-07 · 12 (7) · 1632-1647

DOI: 10.1016/j.jacep.2026.02.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2026-07. Verfasst von Tomoya Iwawaki und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Cardiology, Kainan Hospital, Yatomi, Japan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND The optimal timing for discontinuing oral anticoagulants (OACs) after successful atrial fibrillation ablation remains unclear. OBJECTIVES This study sought to assess the adverse events between patients who discontinued OACs and those who continued across various time points following successful ablation to determine the optimal OAC discontinuation timing. METHODS We retrospectively analyzed 2,448 patients who underwent initial atrial fibrillation ablation between 2006 and 2022. Thromboembolic and bleeding risks were evaluated across 537 time points of a landmark period (1-537 weeks after ablation) using inverse probability of treatment weighting analysis. Optimal OAC discontinuation timing was defined as the point maximizing the "reverse" net clinical benefit, calculated as (bleeding risk difference [(intracranial hemorrhage ×1.5) + (non-intracranial hemorrhage ×0.5)]) - thromboembolic risk difference. RESULTS During a median follow-up period of 34.1 (Q1-Q3: 12.4-81.9) months, thromboembolic and major bleeding events occurred in 66 (2.7%) (0.63 per 100 patient-years) and 62 patients (2.5%) (0.59 per 100 patient-years), respectively. The estimated thromboembolic risk of OAC discontinuation increased at 4-5 months post ablation, whereas bleeding risk gradually decreased alongside the prolonged discontinuation timing. The reverse net clinical benefit peaked at 8.1 months, suggesting this was the optimal discontinuation timing. At this time point, OAC discontinuation was associated with a high thromboembolic risk (HR: 2.364 P = 0.010) and reduced bleeding risk (HR: 0.176; P = 0.002), with no significant differences in mortality (HR: 0.925; P = 0.830). CONCLUSIONS OAC discontinuation at 8.1 months post ablation may represent the optimal timing for a balance between thromboembolic and bleeding risks in this cohort. Individualized risk assessment facilitates OAC management after successful ablation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationAnticoagulantsHumansFemaleMaleRetrospective StudiesThromboembolismAdministration, OralAgedMiddle AgedPrognosisTreatment InterruptionHemorrhageTime Factors

Stichwörter der Autor:innen

atrial fibrillationcatheter ablationmajor bleedingoral anticoagulantsthromboembolism

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Cardiology, Kainan Hospital, Yatomi, Japan.
  • Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Advanced Cardiovascular Therapeutics, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic addres…
  • Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Advanced Cardiovascular Therapeutics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Zitieren

APA

Iwawaki, T., Yanagisawa, S., Inden, Y., Miyamae, K., Miyazawa, H., Goto, T., Kondo, S., Tachi, M., Fukushima, T., Hiramatsu, T., Adachi, K., Teraoka, T., Ota, R., Shimojo, M., Tsuji, Y., Okumura, T., & Murohara, T. (2026). Optimal Timing for Oral Anticoagulant Discontinuation and Prognosis After Successful Catheter Ablation for Atrial Fibrillation. JACC: Clinical Electrophysiology, 12(7), 1632-1647. https://doi.org/10.1016/j.jacep.2026.02.027

Vancouver

Iwawaki T, Yanagisawa S, Inden Y, Miyamae K, Miyazawa H, Goto T, et al. Optimal Timing for Oral Anticoagulant Discontinuation and Prognosis After Successful Catheter Ablation for Atrial Fibrillation. JACC: Clinical Electrophysiology. 2026;12(7):1632-1647. doi:10.1016/j.jacep.2026.02.027

BibTeX
@article{Iwawaki2026,
  author = {Iwawaki, Tomoya and Yanagisawa, Satoshi and Inden, Yasuya and Miyamae, Kiichi and Miyazawa, Hiroyuki and Goto, Takayuki and Kondo, Shun and Tachi, Masaya and Fukushima, Taishi and Hiramatsu, Takehiro and Adachi, Kentaro and Teraoka, Tsubasa and Ota, Ryusuke and Shimojo, Masafumi and Tsuji, Yukiomi and Okumura, Takahiro and Murohara, Toyoaki},
  title = {Optimal Timing for Oral Anticoagulant Discontinuation and Prognosis After Successful Catheter Ablation for Atrial Fibrillation},
  journal = {JACC: Clinical Electrophysiology},
  year = {2026},
  volume = {12},
  number = {7},
  pages = {1632--1647},
  doi = {10.1016/j.jacep.2026.02.027}
}
Kostenlos starten →